Europe Brain Cancer Diagnostic Market - Industry Trends and Forecast to 2030

Description

List of Tables

Europe brain cancer diagnostic market is projected to register a substantial CAGR of 18.2 % in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Europe Brain Cancer Diagnostic Market, By Test Type (Imaging Test, Biopsy, Lumber Puncture, Molecular Testing, Electroencephalography (EEG), and Others), Cancer Type (Acoustic Neuroma, Astrocytomas, Glioblastoma Multiforme, Meningiomas, Oligodendroglioma, and Others), Age Group (Below 21,21-34, 35-65, and 65 and Above), End User (Hospitals, Specialty Clinics, Diagnostic Centers & Research Institutes, Ambulatory Surgical Centers, and Others), Country (Russia, Spain, Turkey, Germany, Italy, United Kingdom, France, Belgium, Switzerland, Netherlands, and the Rest of Europe), Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Europe brain cancer diagnostic market are:

Rising cases of brain cancer worldwide

Rising awareness of early diagnosis of brain cancer

Improved imaging techniques

Innovations in drug delivery to brain cancer cells

Market Players

Some of the key market players for the Europe brain cancer diagnostic market are listed below:

NIHON KOHDEN CORPORATION.

FUJIFILM Holdings Corporation

GE HealthCare

Koninklijke Philips N.V.

Siemens Healthcare GmbH

Canon Inc.

Others

1 INTRODUCTION 24

1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET 24
1.4 CURRENCY AND PRICING 26
1.5 LIMITATIONS 26
1.6 MARKETS COVERED 26

2 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 29

2.1 MARKETS COVERED 29
2.2 GEOGRAPHICAL SCOPE 30
2.3 YEARS CONSIDERED FOR THE STUDY 31
2.4 DBMR TRIPOD DATA VALIDATION MODEL 32
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.6 MULTIVARIATE MODELLING 36
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 36
2.8 DBMR MARKET POSITION GRID 37
2.9 VENDOR SHARE ANALYSIS 39
2.10 MARKET END USER COVERAGE GRID 40
2.11 SECONDARY SOURCES 41

3 EXECUTIVE SUMMARY 42

4 PREMIUM INSIGHTS 44

4.1 PESTEL ANALYSIS 45
4.2 PORTER'S FIVE FORCES 46

5 EPIDEMIOLOGY 47

6 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, INDUSTRY INSIGHT 48

7 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, REGULATIONS 49

7.1 REGULATORY SCENARIO IN THE U.S 49
7.2 REGULATORY SCENARIO IN AUSTRALIA 50
7.3 REGULATORY SCENARIO IN JAPAN 50
7.4 REGULATORY SCENARIO IN CHINA 50

8 MARKET OVERVIEW 52

8.1 DRIVERS 54
- 8.1.1 RISING CASES OF BRAIN CANCER WORLDWIDE 54
- 8.1.2 RISING AWARENESS OF THE EARLY DIAGNOSIS OF BRAIN CANCER 54
- 8.1.3 IMPROVED IMAGING TECHNIQUES 55
- 8.1.4 INNOVATIONS IN DRUG DELIVERY TO BRAIN CANCER CELLS 55
8.2 RESTRAINTS 56
- 8.2.1 HIGH COST ASSOCIATED WITH DIAGNOSIS & TREATMENT FOR BRAIN CANCER 56
- 8.2.2 SIDE EFFECTS OF BRAIN CANCER TREATMENT DRUGS & THERAPIES 56
- 8.2.3 LATE DIAGNOSIS OF BRAIN CANCER RESULTING IN POOR PROGNOSIS 57
8.3 OPPORTUNITIES 57
- 8.3.1 INCREASING INVESTMENT AND FUNDING BY EMERGING PLAYERS 57
- 8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTIC 57
- 8.3.3 RISING HEALTHCARE EXPENDITURE 58
8.4 CHALLENGES 59
- 8.4.1 STRINGENT REGULATORY REQUIREMENTS FOR DIAGNOSTIC PRODUCTS 59
- 8.4.2 OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 59

9 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE 60

9.1 OVERVIEW 61
9.2 IMAGING TEST 64
- 9.2.1 CT SCAN 65
- 9.2.2 MRI 65
- 9.2.3 PET 65
- 9.2.4 OTHERS 65
9.3 MOLECULAR TESTING 66
9.4 ELECTROENCEPHALOGRAPHY (EEG) 66
9.5 LUMBAR PUNCTURE 67
9.6 BIOPSY 68
- 9.6.1 OPEN BIOPSY 69
- 9.6.2 STEREOTACTIC BIOPSY 69
- 9.6.3 NEEDLE BIOPSY 69
- 9.6.4 NEUROENDOSCOPY 69
9.7 OTHERS 69

10 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE 70

10.1 OVERVIEW 71
10.2 GLIOBLASTOMA MULTIFORME 74
10.3 MENINGIOMAS 75
10.4 ASTROCYTOMAS 76
10.5 ACOUSTIC NEUROMA 77
10.6 OLIGODENDROGLIOMA 78
10.7 OLIGODENDROGLIOMA 78
10.8 OTHERS 79

11 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP 80

11.1 OVERVIEW 81
11.2 35-65 84
11.3 65 AND ABOVE 85
11.4 BELOW 21 86
11.5 21-34 87

12 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER 88

12.1 OVERVIEW 89
12.2 HOSPITALS 92
12.3 SPECIALTY CLINICS 93
12.4 DIAGNOSTIC CENTERS & RESEARCH INSTITUTES 94
12.5 AMBULATORY SURGICAL CENTERS 95
12.6 OTHERS 96

13 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY REGION 97

13.1 EUROPE 98
- 13.1.1 GERMANY 105
- 13.1.2 FRANCE 107
- 13.1.3 U.K. 109
- 13.1.4 ITALY 111
- 13.1.5 SPAIN 113
- 13.1.6 RUSSIA 115
- 13.1.7 SWITZERLAND 117
- 13.1.8 NETHERLANDS 119
- 13.1.9 TURKEY 121
- 13.1.10 BELGIUM 123
- 13.1.11 REST OF EUROPE 125

14 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY LANDSCAPE 126

14.1 COMPANY SHARE ANALYSIS: EUROPE 126

15 SWOT ANALYSIS 127

16 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, COMPANY PROFILE 128

16.1 KONINKLIJKE PHILIPS N.V. 128
- 16.1.1 COMPANY SNAPSHOT 128
- 16.1.2 REVENUE ANALYSIS 128
- 16.1.3 COMPANY SHARE ANALYSIS 129
- 16.1.4 PRODUCT PORTFOLIO 129
- 16.1.5 RECENT DEVELOPMENTS 130
16.2 CANON INC. 131
- 16.2.1 COMPANY SNAPSHOT 131
- 16.2.2 REVENUE ANALYSIS 131
- 16.2.3 COMPANY SHARE ANALYSIS 132
- 16.2.4 PRODUCT PORTFOLIO 132
- 16.2.5 RECENT DEVELOPMENT 132
16.3 SIEMENS HEALTHCARE GMBH 133
- 16.3.1 COMPANY SNAPSHOT 133
- 16.3.2 REVENUE ANALYSIS 134
- 16.3.3 COMPANY SHARE ANALYSIS 134
- 16.3.4 PRODUCT PORTFOLIO 135
- 16.3.5 RECENT DEVELOPMENTS 135
16.4 BD 136
- 16.4.1 COMPANY SNAPSHOT 136
- 16.4.2 REVENUE ANALYSIS 137
- 16.4.3 COMPANY SHARE ANALYSIS 137
- 16.4.4 PRODUCT PORTFOLIO 138
- 16.4.5 RECENT DEVELOPMENTS 138
16.5 NIHON KOHDEN CORPORATION. 139
- 16.5.1 COMPANY SNAPSHOT 139
- 16.5.2 RECENT FINANCIALS 139
- 16.5.3 COMPANY SHARE ANALYSIS 140
- 16.5.4 PRODUCT PORTFOLIO 140
- 16.5.5 RECENT DEVELOPMENT 140
16.6 BIOCEPT, INC. 141
- 16.6.1 COMPANY SNAPSHOT 141
- 16.6.2 REVENUE ANALYSIS 141
- 16.6.3 PRODUCT PORTFOLIO 142
- 16.6.4 RECENT DEVELOPMENT 142
16.7 BIOMIND 143
- 16.7.1 COMPANY SNAPSHOT 143
- 16.7.2 PRODUCT PORTFOLIO 143
- 16.7.3 RECENT DEVELOPMENT 143
16.8 CEREBRAL DIAGNOSTIC 144
- 16.8.1 COMPANY SNAPSHOT 144
- 16.8.2 PRODUCT PORTFOLIO 144
- 16.8.3 RECENT DEVELOPMENT 144
16.9 DXCOVER LIMITED 145
- 16.9.1 COMPANY SNAPSHOT 145
- 16.9.2 PRODUCT PORTFOLIO 145
- 16.9.3 RECENT DEVELOPMENT 145
16.10 FONAR CORP. 146
- 16.10.1 COMPANY SNAPSHOT 146
- 16.10.2 REVENUE ANALYSIS 146
- 16.10.3 PRODUCT PORTFOLIO 147
- 16.10.4 RECENT DEVELOPMENT 147
16.11 FUJIFILM CORPORATION 148
- 16.11.1 COMPANY SNAPSHOT 148
- 16.11.2 REVENUE ANALYSIS 148
- 16.11.3 PRODUCT PORTFOLIO 149
- 16.11.4 RECENT DEVELOPMENT 149
16.12 GE HEALTHCARE. 150
- 16.12.1 COMPANY SNAPSHOT 150
- 16.12.2 REVENUE ANALYSIS 150
- 16.12.3 PRODUCT PORTFOLIO 151
- 16.12.4 RECENT DEVELOPMENT 151
16.13 HITACHI, LTD. 152
- 16.13.1 COMPANY SNAPSHOT 152
- 16.13.2 REVENUE ANALYSIS 152
- 16.13.3 PRODUCT PORTFOLIO 153
- 16.13.4 RECENT DEVELOPMENT 153
16.14 MINFOUND MEDICAL SYSTEMS CO., 154
- 16.14.1 COMPANY SNAPSHOT 154
- 16.14.2 PRODUCT PORTFOLIO 154
- 16.14.3 RECENT DEVELOPMENT 154
16.15 NANTOMICS. 155
- 16.15.1 COMPANY SNAPSHOT 155
- 16.15.2 PRODUCT PORTFOLIO 155
- 16.15.3 RECENT DEVELOPMENT 155
16.16 NEUSOFT CORPORATION 156
- 16.16.1 COMPANY SNAPSHOT 156
- 16.16.2 REVENUE ANALYSIS 156
- 16.16.3 PRODUCT PORTFOLIO 157
- 16.16.4 RECENT DEVELOPMENT 157
16.17 SEQUOIA HEALTHCARE. 158
- 16.17.1 COMPANY SNAPSHOT 158
- 16.17.2 PRODUCT PORTFOLIO 158
- 16.17.3 RECENT DEVELOPMENT 158
16.18 STERNMED GMBH 159
- 16.18.1 COMPANY SNAPSHOT 159
- 16.18.2 PRODUCT PORTFOLIO 159
- 16.18.3 RECENT DEVELOPMENT 159
16.19 THERMO FISHER SCIENTIFIC INC. 160
- 16.19.1 COMPANY SNAPSHOT 160
- 16.19.2 REVENUE ANALYSIS 160
- 16.19.3 PRODUCT PORTFOLIO 161
- 16.19.4 RECENT DEVELOPMENT 161
16.20 TIME MEDICAL HOLDING. 162
- 16.20.1 COMPANY SNAPSHOT 162
- 16.20.2 PRODUCT PORTFOLIO 162
- 16.20.3 RECENT DEVELOPMENTS 162

17 QUESTIONNAIRE 163

18 RELATED REPORTS 166

LIST OF TABLES

TABLE 1 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 56
TABLE 2 EUROPE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 57
TABLE 3 EUROPE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 58
TABLE 4 EUROPE MOLECULAR TESTING IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 59
TABLE 5 EUROPE ELECTROENCEPHALOGRAPHY (EEG) IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 6 EUROPE LUMBAR PUNCTURE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 60
TABLE 7 EUROPE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 61
TABLE 8 EUROPE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 61
TABLE 9 EUROPE OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 62
TABLE 10 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 66
TABLE 11 EUROPE GLIOBLASTOMA MULTIFORME IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 67
TABLE 12 EUROPE MENINGIOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 13 EUROPE ASTROCYTOMAS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 14 EUROPE ACOUSTIC NEUROMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 70
TABLE 15 EUROPE OLIGODENDROGLIOMA IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 71
TABLE 16 EUROPE OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 72
TABLE 17 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 76
TABLE 18 EUROPE 35-65 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 77
TABLE 19 EUROPE 65 AND ABOVE IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 78
TABLE 20 EUROPE BELOW 21 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 79
TABLE 21 EUROPE 21-34 IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 22 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 84
TABLE 23 EUROPE HOSPITALS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 85
TABLE 24 EUROPE SPECIALTY CLINICS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 25 EUROPE DIAGNOSTIC CENTERS & RESEARCH INSTITUTES IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 26 EUROPE AMBULATORY SURGICAL CENTERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 27 EUROPE OTHERS IN BRAIN CANCER DIAGNOSTIC MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 28 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 95
TABLE 29 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 95
TABLE 30 EUROPE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 96
TABLE 31 EUROPE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 96
TABLE 32 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 96
TABLE 33 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 97
TABLE 34 EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 97
TABLE 35 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
TABLE 36 GERMANY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
TABLE 37 GERMANY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 98
TABLE 38 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 99
TABLE 39 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 99
TABLE 40 GERMANY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 99
TABLE 41 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
TABLE 42 FRANCE IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
TABLE 43 FRANCE BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 100
TABLE 44 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 101
TABLE 45 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 101
TABLE 46 FRANCE BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 101
TABLE 47 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
TABLE 48 U.K. IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
TABLE 49 U.K. BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
TABLE 50 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 103
TABLE 51 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 103
TABLE 52 U.K. BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 103
TABLE 53 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
TABLE 54 ITALY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
TABLE 55 ITALY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
TABLE 56 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 105
TABLE 57 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 105
TABLE 58 ITALY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 105
TABLE 59 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 106
TABLE 60 SPAIN IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 106
TABLE 61 SPAIN BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 106
TABLE 62 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 107
TABLE 63 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 107
TABLE 64 SPAIN BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 107
TABLE 65 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
TABLE 66 RUSSIA IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
TABLE 67 RUSSIA BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
TABLE 68 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 109
TABLE 69 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 109
TABLE 70 RUSSIA BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 109
TABLE 71 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
TABLE 72 SWITZERLAND IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
TABLE 73 SWITZERLAND BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
TABLE 74 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 111
TABLE 75 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 111
TABLE 76 SWITZERLAND BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 111
TABLE 77 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 112
TABLE 78 NETHERLANDS IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 112
TABLE 79 NETHERLANDS BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 112
TABLE 80 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 113
TABLE 81 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 113
TABLE 82 NETHERLANDS BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 113
TABLE 83 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 84 TURKEY IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 85 TURKEY BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
TABLE 86 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 115
TABLE 87 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 115
TABLE 88 TURKEY BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 115
TABLE 89 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
TABLE 90 BELGIUM IMAGING TEST IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
TABLE 91 BELGIUM BIOPSY IN BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
TABLE 92 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION) 117
TABLE 93 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY AGE GROUP, 2021-2030 (USD MILLION) 117
TABLE 94 BELGIUM BRAIN CANCER DIAGNOSTIC MARKET, BY END USER, 2021-2030 (USD MILLION) 117
TABLE 95 REST OF EUROPE BRAIN CANCER DIAGNOSTIC MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 118

LIST OF FIGURES

FIGURE 1 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 21
FIGURE 2 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 24
FIGURE 3 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 25
FIGURE 4 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 26
FIGURE 5 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 26
FIGURE 6 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 27
FIGURE 7 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: DBMR POSITION GRID 29
FIGURE 8 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 31
FIGURE 9 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: END USER COVERAGE GRID 32
FIGURE 10 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SEGMENTATION 35
FIGURE 11 RISING CASES OF BRAIN CANCER WORLDWIDE & IMPROVED IMAGING TECHNIQUES ARE EXPECTED TO DRIVE THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 36
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 36
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE EUROPE BRAIN CANCER DIAGNOSTIC MARKET 45
FIGURE 14 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, 2022 53
FIGURE 15 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE 2023-2030 (USD MILLION) 54
FIGURE 16 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, CAGR (2023-2030) 54
FIGURE 17 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE, LIFELINE CURVE 55
FIGURE 18 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, 2022 63
FIGURE 19 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE 2023-2030 (USD MILLION) 64
FIGURE 20 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, CAGR (2023-2030) 64
FIGURE 21 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY CANCER TYPE, LIFELINE CURVE 65
FIGURE 22 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2022 73
FIGURE 23 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, 2023-2030 (USD MILLION) 74
FIGURE 24 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, CAGR (2023-2030) 74
FIGURE 25 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY AGE GROUP, LIFELINE CURVE 75
FIGURE 26 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2022 81
FIGURE 27 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, 2023-2030 (USD MILLION) 82
FIGURE 28 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, CAGR (2023-2030) 82
FIGURE 29 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE 83
FIGURE 30 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: SNAPSHOT (2022) 91
FIGURE 31 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022) 92
FIGURE 32 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2023 & 2030) 92
FIGURE 33 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2030) 93
FIGURE 34 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: BY TEST TYPE (2023-2030) 93
FIGURE 35 EUROPE BRAIN CANCER DIAGNOSTIC MARKET: COMPANY SHARE 2022 (%) 118